 |
The five-year framework agreement covers phased rollout of Lunit's AI suite—including chest X-ray, mammography, tomosynthesis, and fracture detection—across 79 Starvision sites
SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a strategic partnership with Starvision Service GmbH, Germany's largest private radiology network. Through a newly signed framework agreement, Lunit's AI imaging solutions will be deployed across Starvision's expansive network of radiological practices.
Starvision operates 79 locations across seven German federal states, delivering services in radiology, nuclear medicine, and radiation therapy. As a recognized leader in the DACH healthcare market, Starvision is known for its commitment to digital transformation, operational excellence, and high-quality patient care.
Under the agreement, Starvision will adopt several of Lunit's AI solutions, including:
- Lunit INSIGHT CXR: AI-based chest X-ray analysis
- Lunit INSIGHT MMG: Mammography analysis solution
- Lunit INSIGHT DBT: Digital breast tomosynthesis interpretation
- RBfracture: AI-driven fracture detection
The first commercial deployments are already underway—including use of Lunit INSIGHT MMG at Radiologische Allianz in Hamburg, supporting the Hamburg breast cancer screening program under the Starvision network. Together with deployments at Die Radiologie, a major regional hospital group operating over 20 medical sites across Bavaria, Lunit's solutions are now supporting approximately 120,000 breast cancer screenings and diagnoses annually across the two institutions.
The five-year framework agreement allows additional Starvision locations—and newly affiliated practices—to join at any time, enabling broad scalability across the network. New deployments and clinical trials are already in progress, with individual agreements being signed across Starvision's entities as part of a phased implementation plan. Beyond Starvision, several other healthcare providers across Germany have also expressed interest, reflecting the expanding demand for AI-driven imaging solutions.
"Lunit's AI solutions support our radiologists in delivering fast and accurate diagnoses. This strengthens diagnostic confidence and gives us more time to focus on what truly matters: the individual care of our patients," said Uwe Pfeifer, CEO of Starvision Service GmbH.
"Partnering with Starvision accelerates our vision of bringing AI-powered precision diagnostics into everyday clinical practice," said Brandon Suh, CEO of Lunit. "Together, we are advancing a new era of radiology where technology enhances the expertise of physicians, delivering better outcomes for millions of patients in Germany and beyond."
The partnership supports both companies' vision of transforming healthcare through intelligent technology and setting new standards in radiology.
###
About Lunit
Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 4,800 medical institutions in more than 55 countries. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology—and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.
The five-year framework agreement covers phased rollout of Lunit's AI suite—including chest X-ray, mammography, tomosynthesis, and fracture detection—across 79 Starvision sites
SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a strategic partnership with Starvision Service GmbH, Germany's largest private radiology network. Through a newly signed framework agreement, Lunit's AI imaging solutions will be deployed across Starvision's expansive network of radiological practices.
Starvision operates 79 locations across seven German federal states, delivering services in radiology, nuclear medicine, and radiation therapy. As a recognized leader in the DACH healthcare market, Starvision is known for its commitment to digital transformation, operational excellence, and high-quality patient care.
Under the agreement, Starvision will adopt several of Lunit's AI solutions, including:
- Lunit INSIGHT CXR: AI-based chest X-ray analysis
- Lunit INSIGHT MMG: Mammography analysis solution
- Lunit INSIGHT DBT: Digital breast tomosynthesis interpretation
- RBfracture: AI-driven fracture detection
The first commercial deployments are already underway—including use of Lunit INSIGHT MMG at Radiologische Allianz in Hamburg, supporting the Hamburg breast cancer screening program under the Starvision network. Together with deployments at Die Radiologie, a major regional hospital group operating over 20 medical sites across Bavaria, Lunit's solutions are now supporting approximately 120,000 breast cancer screenings and diagnoses annually across the two institutions.
The five-year framework agreement allows additional Starvision locations—and newly affiliated practices—to join at any time, enabling broad scalability across the network. New deployments and clinical trials are already in progress, with individual agreements being signed across Starvision's entities as part of a phased implementation plan. Beyond Starvision, several other healthcare providers across Germany have also expressed interest, reflecting the expanding demand for AI-driven imaging solutions.
"Lunit's AI solutions support our radiologists in delivering fast and accurate diagnoses. This strengthens diagnostic confidence and gives us more time to focus on what truly matters: the individual care of our patients," said Uwe Pfeifer, CEO of Starvision Service GmbH.
"Partnering with Starvision accelerates our vision of bringing AI-powered precision diagnostics into everyday clinical practice," said Brandon Suh, CEO of Lunit. "Together, we are advancing a new era of radiology where technology enhances the expertise of physicians, delivering better outcomes for millions of patients in Germany and beyond."
The partnership supports both companies' vision of transforming healthcare through intelligent technology and setting new standards in radiology.
###
About Lunit
Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 4,800 medical institutions in more than 55 countries. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology—and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Lunit to Power Germany's Largest Private Radiology Network with AI Imaging
|
APIA, Samoa, Dec. 31, 2025 /PRNewswire/ -- Phemex, a user-first crypto exchange, has introduced a structured reward initiative for the newly listed LIT and MAGMA trading pairs. Running from December 31, 2025, to January 7, 2026, the program features a total allocation of 30,000 USDT designed to support liquidity and market engagement within its derivatives ecosystem.
The initiative highlights two infrastructure approaches in the DeFi sector. Lighter (LIT) is an order-book DEX infrastructure focused on institutional-grade capital efficiency and low-latency execution. Magma Finance (MAGMA) is an AMM DEX built for MOVE-based blockchains, utilizing a liquidity incentive engine designed to align the interests of traders, governance participants, and liquidity providers.
To ensure balanced participation, Phemex has partitioned the 30,000 USDT allocation into two categories:
Reward Mechanism Details:
- Engagement-Based Pool (10,000 USDT): Dedicated to general interaction tasks, including social referrals and daily trading milestones. This pool is intended to broaden the user base for these emerging protocols.
- Volume-Driven Competition (20,000 USDT): A competitive track focused on futures trading volume for LIT and MAGMA. Rewards are distributed based on ranking performance, with the top three participants eligible for a significant portion of the pool, including a maximum individual reward of 4,000 USDT.
By integrating these specialized protocols, Phemex continues to diversify its high-performance trading environment, providing users with exposure to the latest developments in order-book and MOVE-based AMM technologies.
About Phemex
Founded in 2019, Phemex is a user-first crypto exchange trusted by over 10 million traders worldwide. The platform offers spot and derivatives trading, copy trading, and wealth management products designed to prioritize user experience, transparency, and innovation. With a forward-thinking approach and a commitment to user empowerment, Phemex delivers reliable tools, inclusive access, and evolving opportunities for traders at every level to grow and succeed.
For more information, please visit: https://phemex.com/
APIA, Samoa, Dec. 31, 2025 /PRNewswire/ -- Phemex, a user-first crypto exchange, has introduced a structured reward initiative for the newly listed LIT and MAGMA trading pairs. Running from December 31, 2025, to January 7, 2026, the program features a total allocation of 30,000 USDT designed to support liquidity and market engagement within its derivatives ecosystem.
The initiative highlights two infrastructure approaches in the DeFi sector. Lighter (LIT) is an order-book DEX infrastructure focused on institutional-grade capital efficiency and low-latency execution. Magma Finance (MAGMA) is an AMM DEX built for MOVE-based blockchains, utilizing a liquidity incentive engine designed to align the interests of traders, governance participants, and liquidity providers.
To ensure balanced participation, Phemex has partitioned the 30,000 USDT allocation into two categories:
Reward Mechanism Details:
- Engagement-Based Pool (10,000 USDT): Dedicated to general interaction tasks, including social referrals and daily trading milestones. This pool is intended to broaden the user base for these emerging protocols.
- Volume-Driven Competition (20,000 USDT): A competitive track focused on futures trading volume for LIT and MAGMA. Rewards are distributed based on ranking performance, with the top three participants eligible for a significant portion of the pool, including a maximum individual reward of 4,000 USDT.
By integrating these specialized protocols, Phemex continues to diversify its high-performance trading environment, providing users with exposure to the latest developments in order-book and MOVE-based AMM technologies.
About Phemex
Founded in 2019, Phemex is a user-first crypto exchange trusted by over 10 million traders worldwide. The platform offers spot and derivatives trading, copy trading, and wealth management products designed to prioritize user experience, transparency, and innovation. With a forward-thinking approach and a commitment to user empowerment, Phemex delivers reliable tools, inclusive access, and evolving opportunities for traders at every level to grow and succeed.
For more information, please visit: https://phemex.com/
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Phemex Launches 30,000 USDT Incentive Program for LIT and MAGMA Trading Pairs
